Locilex

Locilex

Cytolex, MSI-78, pexiganan acetate Infectious disease A topical antibiotic for treating infected diabetic foot ulcers; Locilex is the first in a class of antibiotic/anti-infective magainins, derived from the skin secretions of the African clawed frog, which kill bacteria by attacking cell membranes. See Magainin. Note: It was deemed not approvable.
References in periodicals archive ?
NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialisation of Locilex (pexiganan cream 0.
a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.
M2 PHARMA-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
The first two topical antibacterials, Innocoll's Cogenzia (gentamicin-collagen sponge) and Dipexium Pharmaceuticals' Locilex (pexiganan acetate cream 1%), are also expected to launch in the US and the five major EU markets (5EU).
She has been assigned to work on the SmithKline Beecham Locilex account.
M2 PHARMA-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium recently completed its pivotal Phase 3 clinical trials (OneStep-1 and OneStep-2) with Locilex in mild infections of diabetic foot ulcers in the United States under a Special Protocol Assessment (SPA) agreement from the US Food and Drug Administration (FDA).
Dipexium" or the "Company"), a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.
M2 EQUITYBITES-February 5, 2016-Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
M2 EQUITYBITES-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
M2 EQUITYBITES-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex